| Code | CSB-RA622651MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Cofetuzumab, targeting protein tyrosine kinase 7 (PTK7), also known as colon carcinoma kinase-4 (CCK-4). PTK7 is a catalytically inactive receptor tyrosine kinase that functions as a critical regulator of planar cell polarity and Wnt signaling pathways. Despite lacking intrinsic kinase activity, PTK7 serves as a scaffold protein involved in cell migration, adhesion, and differentiation processes. Aberrant PTK7 expression has been documented across multiple malignancies, including colorectal, ovarian, lung, and esophageal cancers, where it contributes to tumor progression, metastasis, and poor prognosis, making it an attractive oncology target.
Cofetuzumab is a humanized IgG1 monoclonal antibody that specifically recognizes the extracellular domain of PTK7 and was developed as part of antibody-drug conjugate strategies for cancer therapy. This biosimilar provides researchers with a valuable tool for investigating PTK7-mediated signaling mechanisms, exploring its role in developmental biology and oncogenesis, and supporting preclinical studies in targeted cancer therapeutics.
There are currently no reviews for this product.